Citius Pharmaceuticals’ Lymphir and Keytruda Combo Shows Promising Clinical Outcomes, Earning a Buy Rating
Michael Okunewitch, an analyst from Maxim Group, maintained the Buy rating on Citius Pharmaceuticals (CTXR – Research Report). The ...
FierceBiotech5d
NextCure goes all in on B7-H4, stopping other programs to challenge Big Pharma in ADC space
NextCure is going all in on its preclinical B7-H4-directed antibody-drug conjugate (ADC). | NextCure is going all in on its ...
Business Insider6d
IO Biotech reports data on IO102-IO103 vaccine in combination with KEYTRUDA
IO Biotech (IOBT) announced data from the NSCLC cohort in the company’s Phase 2 basket trial of IO102-IO103, the company’s lead investigational candidate, given in combination with Merck’s anti-PD-1 ...